Equities Analysts Offer Predictions for CGTX Q1 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities researchers at HC Wainwright dropped their Q1 2025 EPS estimates for Cognition Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.12) per share for the quarter, down from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.28) EPS.

Other equities analysts have also recently issued research reports about the company. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $1.00 to $1.50 in a report on Thursday, December 19th. Chardan Capital decreased their target price on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Cognition Therapeutics has a consensus rating of “Buy” and an average price target of $7.50.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX opened at $0.46 on Wednesday. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The company has a market capitalization of $19.08 million, a price-to-earnings ratio of -0.47 and a beta of 1.03. The business has a 50-day moving average of $0.57 and a 200-day moving average of $0.55.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period in the previous year, the firm earned ($0.27) EPS.

Institutional Trading of Cognition Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new position in Cognition Therapeutics during the 4th quarter worth $26,000. Two Sigma Investments LP grew its stake in Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after purchasing an additional 42,321 shares in the last quarter. Virtu Financial LLC bought a new stake in Cognition Therapeutics in the third quarter valued at about $27,000. Geode Capital Management LLC increased its holdings in Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after buying an additional 28,705 shares during the last quarter. Finally, Voss Capital LP acquired a new stake in Cognition Therapeutics during the fourth quarter valued at approximately $351,000. 43.35% of the stock is owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.